BCT and BCTXL Related Headlines
Go Back- BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
- BriaCell reports extended survival in metastatic breast cancer trial
- BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
- BriaCell completes $30 million public offering of units
- BriaCell Therapeutics Announces Closing of US$30 million Public Offering
- BriaCell prices $30 million public offering at $5.59 per unit
- BriaCell Therapeutics Announces Pricing of $30 million Public Offering
BCT and BCTXL Related Press Releases
Go Back- BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
- BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
- BriaCell Therapeutics Announces Closing of US$30 million Public Offering
- BriaCell Therapeutics Announces Pricing of $30 million Public Offering

